Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

Bussu, F., Tagliaferri, L., Mattiucci, G., Parrilla, C., Rizzo, D., Gambacorta, M. A., Lancellotta, V., Autorino, R., Fonnesu, C., Kihlgren, C., Galli, J., Paludetti, G., Kovacs, G., Valentini, V., HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies, <<HEAD & NECK>>, 2019; 41 (6): 1667-1675. [doi:10.1002/hed.25646] [http://hdl.handle.net/10807/149286]

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Bussu F.;Tagliaferri L.;Mattiucci G.;Parrilla C.;Gambacorta M. A.;Galli J.;Paludetti G.;Valentini V.
2019

Abstract

Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.
eng
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0347
Bussu, F., Tagliaferri, L., Mattiucci, G., Parrilla, C., Rizzo, D., Gambacorta, M. A., Lancellotta, V., Autorino, R., Fonnesu, C., Kihlgren, C., Galli, J., Paludetti, G., Kovacs, G., Valentini, V., HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies, <>, 2019; 41 (6): 1667-1675. [doi:10.1002/hed.25646] [http://hdl.handle.net/10807/149286]
File in questo prodotto:
File Dimensione Formato  
149286.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 1.22 MB
Formato Unknown
1.22 MB Unknown   Visualizza/Apri   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/149286
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact